Overview
Definitive Healthcare Q3 revenue declines 4% yr/yr but slightly beats analyst expectations
Net loss for Q3 reduced significantly from prior year due to goodwill impairment charges
Adjusted EBITDA for Q3 exceeds expectations by $2 mln
Outlook
Company expects Q4 revenue between $59.0 mln and $60.0 mln
Definitive Healthcare raises bottom end of FY revenue forecast by $2.0 mln
Company sees FY adjusted EBITDA between $68.0 mln and $69.0 mln
Result Drivers
CUSTOMER WINS - Co reports new customer acquisitions and expansion opportunities across all end-markets, driven by data and integration capabilities
STRATEGIC INITIATIVES - CEO Kevin Coop cites progress in new logo production and retention rates as key drivers of Q3 performance
COMPETITIVE DISPLACEMENTS - Co secured competitive displacements by providing critical insights and data integration, enhancing customer value
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$60.05 mln
$59.50 mln (12 Analysts)
Q3 Net Income
-$17.79 mln
Q3 Gross Profit
$45.99 mln
Q3 Pretax Profit
-$17.27 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy."
Wall Street's median 12-month price target for Definitive Healthcare Corp is $4.50, about 39.6% above its November 5 closing price of $2.72
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 16 three months ago
Press Release: ID:nGNX5PNkjm
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)